Germany’s Bayer won fast-track status from U.S. drugs regulators for a new blood thinner designed to prevent certain types of strokes, as the company seeks to follow up on the success of the anticoagulant Xarelto.
https://www.pharmalive.com/wp-content/uploads/2021/12/Blood-thinner-drug-Xarelto-tied-to-higher-rate-of-major-side-effects-study-Reuters-12-21-21.jpg503960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-02-10 03:28:002022-02-10 12:48:13Bayer gets FDA fast track status for next-generation blood thinner